On an annual basis, revenue rose from KRW 4.88 billion in 2023 to KRW 9.54 billion in 2024 (up 95.5%) and KRW 16.5 billion in 2025 (up 72.7%), marking two consecutive years of growth, with 2025 the largest year in the 2023 to 2025 period.
The operating loss narrowed from KRW 5.23 billion in 2023 to KRW 3.57 billion in 2024 and KRW 720 million in 2025, and the company has recorded losses for three consecutive years. The operating margin improved from -107.1% to -37.5% and then to -4.4%.
The main driver cited for revenue growth was higher Nexpowder exports. SG&A rose about 31% year on year on R&D and clinical spending, which the company described as investment in new products and global regulatory approvals.
The net loss attributable to controlling shareholders of KRW 7.52 billion in 2023 turned into a net income of KRW 2.86 billion in 2024, then returned to a net loss of KRW 311 million in 2025. Net income including non-controlling interests moved in the same direction.
Operating cash flow went from -KRW 4.16 billion in 2023 and -KRW 1.2 billion in 2024 to KRW 1.25 billion in 2025, a positive swing.
On a quarterly basis, the company posted its first quarterly operating profit of KRW 370 million in the third quarter of 2025, then an operating loss of KRW 442 million in the fourth quarter.
Operating losses were KRW 1.19 billion, KRW 1.03 billion and KRW 866 million in the first through third quarters of 2026, so the loss has narrowed since the second quarter.
Revenue bottomed at KRW 3.8 billion in the fourth quarter of 2025 (down 23.0% from the prior quarter) and then rose to KRW 4.12 billion, KRW 4.94 billion and KRW 5.25 billion across the first three quarters of 2026.
The net loss attributable to controlling shareholders reached KRW 3.47 billion in the third quarter of 2026, far larger than the operating loss, so the effect of non-operating items should be checked in the periodic report.
The combined net loss attributable to controlling shareholders over the last four quarters was KRW 4.29 billion.